# A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

> **NCT05896163** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** maplirpacept (PF-07901801)
- **DRUG:** Glofitamab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05896163
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-30
- **Primary completion:** 2026-04-09
- **Final completion:** 2026-04-09
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896163, "A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05896163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*